



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Corp. Off : No.3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600 033.

Date: 07th March 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers
21st Floor, Dalal Street
Mumbai – 400001

BSE Scrip Code: 524322

Sub: Outcome of Board Meeting held on 07th March 2026, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30, read with Schedule III of SEBI (Listing Obligation and Disclosure Requirement), 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. 07th March 2026, has inter-alia transacted the following business:

1. Change of Name of the Company

The Board took note of name approval granted by the Ministry of Corporate Affairs, based on application made for reservation of name 'Aanjaay Industries Limited'. Enclosed the name approval letter obtained from the Ministry of Corporate Affairs as Annexure-1.

2. Strategic expansion of the Company's business operations in Indonesia

The Board considered and approved the strategic expansion of the Company's business operations in the field of defence technology development, engineering & manufacturing of defence systems in India, participation in defence procurement programs and export of jointly developed defence systems by a bilateral Strategic Comprehensive Joint Venture Agreement between the PT. Bhinneka Dwi Persada Indonesia and the Kabra Drugs Limited.

PT. Bhinneka Dwi Persada is engaged in the fields of Engineering, Procurement, manufacture and develop the Strategic Defense Equipment products including Rajawali 330 Uav, Rajawali Cargo Drone, Hovercraft Rajawali Td1000, And MCCV; and is the holder of intellectual property rights over Strategic Defense Equipment Technology in Indonesia.



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Corp. Off : No.3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600 033.

Strategic Alignment: This partnership supports the "Make in India" initiative and the Bilateral Strategic Comprehensive Partnership between Indonesia and India.

The details required to be disclosed under the Listing Regulations read with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 on the captioned subject are enclosed to this intimation as Annexure II.

The meeting of the Board of Directors of the Company commenced at 05.00 p.m. (IST) and concluded at 06:30 p.m. (IST).

Kindly take the aforesaid information on record and oblige.

Thanking you,

Yours sincerely,

For Kabra Drugs Limited



Nanjappan Aravind

Managing Director

DIN: 01895602

Annexure-I

GOVERNMENT OF INDIA
MINISTRY OF CORPORATE AFFAIRS

OFFICE OF THE REGISTRAR OF COMPANIES

CRC Manesar

Plot No. 6,7, 8, Sector 5, IMT Manesar, IMT Manesar, District Gurgaon (Haryana), Manesar, Haryana, India, 122050

Dated: 06/03/2026

To,

A KUMAR REDDY, 16, 1st Floor, Metha Nagar Main Rd, Nelson Manickam Road, Chennai, Egmore
Nungambakkam, Egmore Nungambakkam, Tamil Nadu, India, 600029

Subject: Company's name change- AANJAAY INDUSTRIES LIMITED – Availability of name under Section 4(5) of the Companies Act, 2013

Sir/Madam

1. With reference to your application dated 03/03/2026 AC2527411 It is informed that there is no objection in the availability of the changed name AANJAAY INDUSTRIES LIMITED from the existing name KABRA DRUGS LIMITED to your company.
2. Still it must be taken care that the proposed name cannot be made available for a period exceeding 60 days from the date of approval and this approval does not grant any kind of right of privilege. The name is liable to be withdrawn at any time before approval of the name change, if it is found later on that the name ought not to have been allowed
3. It is allowed subject to the compliance of Section 4(2), 4(3) and other applicable provisions of the Companies Act, 2013.

Yours sincerely,

Document certified by DS MINISTRY OF CORPORATE
AFFAIRS, CRC MANESAR 2 <ROC-CRC@MCA.GOV.IN>

Digitally signed by
DS MINISTRY OF CORPORATE
AFFAIRS, CRC MANESAR 2
Date: 2026.03.06 10:45:06 IST

Nupur Aishwarya

Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies

Registrar of Companies


Central Registration Centre, Ministry of Corporate Affairs

Note: The corresponding form has been approved by Nupur Aishwarya, Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies and this letter has been digitally signed by the Registrar through a system generated digital signature under rule 9(2) of the Companies (Registration Offices and Fees) Rules, 2014



ANNEXURE - II

S.No	Particulars	Details
5.1	Name(s) of parties with whom the agreement is entered	The agreement has been entered into between Kabra Drugs Limited , India and PT. Bhinneka Dwi Persada , Indonesia.
5.2	Purpose of entering into the agreement	The purpose of the agreement is to collaborate for development, manufacturing, procurement, and supply of strategic defence equipment and related technologies by leveraging the expertise and capabilities of both parties.
5.3	Shareholding, if any, in the entity with whom the agreement is executed	Currently, Kabra Drugs Limited does not hold any shareholding in PT. Bhinneka Dwi Persada , Indonesia. The parties may explore incorporation of a joint venture entity, subject to mutually agreed terms.
5.4	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	The parties have agreed to collaborate for strategic cooperation in the defence sector including development, manufacturing, procurement and supply of defence-related products and technologies. The detailed terms including capital contribution, governance structure, and rights such as appointment of directors, subscription rights, and restrictions on change in capital structure of the new joint venture entity will be mutually agreed and documented separately, if required. At present, the agreement does not provide to PT. Bhinneka Dwi Persada , any special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc of Kabra Drugs Limited .
5.5	Whether the said parties are related to promoter/promoter group/group companies	PT. Bhinneka Dwi Persada is not related to the promoter/promoter group/group companies of Kabra Drugs Limited .
5.6	Whether the transaction	No. The transaction does not fall within the



	would fall within related party transactions	ambit of related party transactions.
5.7	In case of issuance of shares, details of issue price and class of shares issued	Not applicable at present. No shares are being issued as per the agreement.
5.8	Any other disclosures related to such agreements viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	At present, the agreement does not provide for appointment of any nominee director on the Board of Kabra Drugs Limited . There are no known potential conflicts of interest arising out of the agreement.
5.9	In case of termination or amendment of agreement listed entity shall disclose additional details to the stock exchange(s)	Not Applicable

